CRBU — Caribou Biosciences Income Statement
0.000.00%
Last trade - 00:00
- $335.07m
- $6.24m
- $34.48m
- 43
- 23
- 60
- 37
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 5.79 | 12.4 | 9.6 | 13.9 | 34.5 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 40.1 | 48.5 | 75 | 120 | 151 |
Operating Profit | -34.3 | -36.1 | -65.4 | -106 | -116 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -31 | -36.1 | -66.6 | -99.4 | -102 |
Provision for Income Taxes | |||||
Net Income After Taxes | -23.4 | -34.3 | -66.9 | -99.4 | -102 |
Net Income Before Extraordinary Items | |||||
Net Income | -23.4 | -34.3 | -66.9 | -99.4 | -102 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -23.4 | -34.3 | -66.9 | -99.4 | -102 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.413 | -0.605 | -1.13 | -1.64 | -1.38 |
Dividends per Share |